BillionToOne
The Development Associate, Oncology supports clinical patient testing within a high throughput CLIA lab by contributing to molecular assay development, data analysis, and experimental design. This on-site role in Menlo Park, CA, involves collaborating with cross-functional teams to validate assays, ensure regulatory compliance, and transfer developed workflows into clinical operations. The position offers opportunities to deepen expertise in molecular biology, computational analysis, and automation within a fast-paced, innovative environment.
Headquarters
Menlo Park, California, United States
Company Size
201-500 employees
Founded
2016
BillionToOne is a molecular diagnostics company that develops blood-based tests for prenatal screening and oncology, with a focus on detecting rare genetic variants in cell-free DNA. Its proprietary Quantitative Counting Template technology powers noninvasive prenatal screening and liquid biopsy assays used by healthcare providers and clinical laboratories. The company operates in the genomics and precision diagnostics industry.
BillionToOne Market Share Gains Raise Questions On Undervalued BLLN Stock
4 days ago
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Nov 6, 2025
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148
9 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BillionToOne.
BillionToOne Shares Surge Following Firm's $273M IPO
Nov 6, 2025